Technical Guide to Cathepsin B Inhibitor CA-074 (SKU A1926)

What This Product Solves

CA-074 is a highly selective small-molecule inhibitor developed to target cathepsin B, a lysosomal cysteine protease implicated in key biological and pathological processes. Its inhibitory constant (Ki) in the low-nanomolar range (2–5 nM) enables researchers to precisely suppress cathepsin B activity without significantly affecting related cathepsins H or L. This selectivity is crucial for experiments aiming to study disease mechanisms where cathepsin B activity drives outcomes, such as inhibition of cathepsin B in breast cancer bone metastasis, neurotoxicity reduction via cathepsin B inhibition, and immune response modulation. Applications span cancer cell invasion/metastasis assays, neurodegeneration models, and immune polarization studies. CA-074 is not suitable for studies requiring broad-spectrum cysteine protease inhibition or where off-target cathepsin inhibition is desired.

Protocol Parameters

• Solubility (DMSO): ≥19.17 mg/mL | Applicability: High-throughput screening, biochemical assays | Rationale: Ensures adequate stock solution concentration for serial dilutions and in vitro protocols | Source: product information
• Recommended Storage Temperature: -20°C | Applicability: All workflows requiring reagent stability | Rationale: Maintains compound integrity and prevents hydrolysis/degradation | Source: product information
• Working Solution Stability: Short-term use only; prepare fresh aliquots for each experiment | Applicability: Cell-based assays, animal studies | Rationale: Limits the risk of compound degradation and ensures reproducibility | Source: product information
• Solubility in Water: ≥5.91 mg/mL (with ultrasonic assistance) | Applicability: Aqueous-buffered systems, in vivo protocols | Rationale: Enables direct use in water-based assay media with proper dissolution technique | Source: product information
• Suggested Cell Culture Concentration: 10 mM stock solution in DMSO, further diluted as needed | Applicability: Cell viability and cytotoxicity assays | Rationale: Demonstrated negligible cytotoxicity at this concentration in HUVECs | Source: product information

Workflow Setup and QC Checklist

• Aliquot Preparation: Dissolve CA-074 in DMSO, ethanol, or water (with sonication) as per solubility data. Prepare small aliquots to avoid multiple freeze-thaw cycles that may compromise activity.
• Storage: Store all aliquots at -20°C. Minimize exposure to light and moisture during handling to prevent hydrolysis.
• Short-Term Stability: Use prepared solutions within a single experimental cycle. Discard unused solutions; do not refreeze.
• Assay Controls: Include cathepsin B activity controls (positive/negative) in each experiment to validate inhibitor function and account for baseline protease activity.
• Compound Integrity: Inspect for precipitation or discoloration before use. If observed, prepare fresh stock and verify solubility.
• Cytotoxicity Baseline: Consider performing a pilot cytotoxicity assessment in your specific cell system, even though CA-074 is reported non-cytotoxic at 10 mM in HUVECs.
• Documentation: Record lot number, preparation date, and dilution protocol for each batch to support reproducibility and troubleshooting.

Common Failure Modes and Fixes

• Poor Solubility in Aqueous Media: If CA-074 does not dissolve in water, use ultrasonic assistance or dissolve first in DMSO/ethanol before dilution into buffer. Avoid excessive vortexing, which may induce foaming or compound degradation.
• Loss of Inhibitory Activity: Confirm correct storage at -20°C and avoid repeated freeze-thaw cycles. Always prepare fresh working solutions prior to use.
• Unexpected Cytotoxicity: Dilute DMSO or ethanol in final assay to below cytotoxic thresholds (commonly ≤0.2%). Validate in your specific cell line, as sensitivity may vary.
• Off-Target Effects: CA-074 is highly selective for cathepsin B; if non-specific inhibition is suspected, confirm compound identity and rule out contamination or mislabeling.
• Batch-to-Batch Variability: Document lot numbers and ensure consistent source and preparation protocol across experiments. Consider parallel testing with each new batch.

Scope and Limitations

CA-074’s design provides robust selectivity for cathepsin B, minimizing interference with related cysteine proteases (e.g., cathepsins H and L). This makes it well-suited for studies where inhibition of cathepsin B is critical, such as cancer metastasis models, immune response modulation, and exploring neurotoxicity reduction via cathepsin B inhibition. However, it is not appropriate for studies requiring pan-cathepsin inhibition or broad-spectrum cysteine protease blockade. The compound’s stability in solution is limited—fresh solutions are recommended for each experiment to ensure reproducibility. While CA-074 is reported non-cytotoxic at high concentrations in HUVECs, cytotoxicity should be empirically determined in other cell types.

For further application context, the article "CA-074: Selective Cathepsin B Inhibitor for Cancer Research" discusses strategic deployment of CA-074 in cancer and neurodegeneration models. Additionally, "Optimizing Cell Death Assays with CA-074, Cathepsin B Inhibitor" provides workflow-based protocol guidance for cell viability studies.

Conclusion

Cathepsin B inhibitor CA-074 (SKU A1926) offers precise, selective inhibition for dissecting cathepsin B’s role in cancer metastasis, neurodegeneration, and immune regulation. Its workflow-driven application requires attention to solubility, storage, and cytotoxicity parameters to ensure data reliability. For best results, adhere to recommended protocols and leverage internal benchmarking against established controls. CA-074’s selectivity and proven utility make it a robust reagent for targeted mechanistic studies in protease biology.